Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Computer Assisted Tomography
52%
Fluorodeoxyglucose F 18
43%
Polyethylene Terephthalate
38%
Positron Emission Tomography
28%
Fluorine-18
23%
Diseases
22%
Gallium 68
20%
Colorectal Carcinoma
20%
Neoplasm
20%
Neck
19%
Fluorodeoxyglucose
16%
Bone Scintigraphy
15%
Recurrent Disease
14%
Rituximab
14%
Metastatic Carcinoma
13%
Prostate Cancer
13%
Squamous Cell
13%
Cancer Cell
13%
Deoxyglucose
13%
Technetium-99
11%
Radiation Therapy
10%
Traumatic Brain Injury
10%
Technetium
10%
Low Drug Dose
9%
Radioisotope
9%
Treatment Response
9%
Pelvis
9%
Standardized Uptake Value
9%
Progression Free Survival
9%
Scintiscanning
8%
Treatment Planning
8%
Malignant Neoplasm
8%
Single-Photon Emission Computed Tomography
7%
Survival Rate
7%
Breast Cancer
7%
Liver Metastasis
7%
Clinical Management
7%
Pentetic Acid
7%
Computed Tomography Studies
7%
Image Quality
7%
Patient Care
7%
Solid Malignant Neoplasm
6%
Pulmonary Embolism
6%
Synoviorthesis
6%
Burkitt's Lymphoma
6%
Lymphangiomatosis
6%
Pyelonephritis
6%
Transjugular Intrahepatic Portosystemic Shunt
6%
Gout
6%
Keyphrases
Positron Emission Tomography-computed Tomography (PET-CT)
92%
Bone Scan
34%
Computed Tomography
25%
Single-photon Emission Computed Tomography (SPECT)
24%
Technetium-99m
22%
18F-FDG PET-CT
21%
Fluorodeoxyglucose
18%
FDG PET-CT
18%
SUVmax
15%
Lymphoma
15%
FDG Uptake
15%
Positron Emission Tomography
15%
Patient Assessment
15%
PET-computed Tomography
14%
Rituximab
14%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
13%
Colorectal Carcinoma
13%
Obsessive-compulsive Disorder
13%
Tc-99m DTPA
13%
Head-and-neck
13%
Stress Fracture
13%
Squamous Cell Cancer
13%
Head-and-neck Cancer
13%
Disease Diagnosis
13%
Fluorine-18
13%
Pitfalls in Interpretation
13%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
12%
Tumor
12%
Older Men
12%
CT Studies
12%
Technetium
11%
Computerized Tomography
11%
Spleen
11%
Pathologic
11%
Patient Management
10%
Detection Rate
10%
Anatomic
9%
18F-fluorodeoxyglucose (18F-FDG)
9%
Brain Imaging
9%
Response to Treatment
9%
Lymph Node Location
9%
Progression-free Survival
9%
CT Findings
9%
Medical Center
8%
Fluorine-18 Fluorodeoxyglucose
8%
Standardized Uptake Value
8%
Radionuclide Imaging
8%
Therapeutic Approaches
8%
Prostate Cancer
8%
Soft Tissue Mass
8%